文献速递慢性肾脏病肾小球疾病遗传性与小管间质肾病

基因检测在多囊肾病中的价值:PKD2与COL4A1突变家系示例

The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.
PubMed 文献 · Am J Kidney Dis · 2018-02-01

该研究通过一个7代家系的临床与遗传学分析,发现同一家系中存在两种囊性疾病:ADPKD-PKD2与COL4A1相关HANAC综合征,并识别出可能双基因PKD2/COL4A1疾病患者。靶向二代测序有助于鉴别诊断并揭示疾病变异性因素,在ADPKD特异性治疗发展的背景下,精确病因诊断对患者管理至关重要。

要点

  • ADPKD临床诊断依赖影像学,分子分析可发现超过90%的PKD1/PKD2突变。
  • 对缺乏家族PKD2突变的ADPKD样表型患者行靶向测序,可发现COL4A1等意外突变。
  • 可能双基因PKD2/COL4A1患者约50岁达终末期肾病,早于任一单基因病。

核心结论

  • 在囊性肾病患者中应用靶向二代测序可提供鉴别诊断并识别疾病变异性因素。
  • 精确病因诊断对于ADPKD患者纳入治疗试验和优化管理至关重要。

研究设计与样本

  • 对一个7代家系进行临床与遗传学分析。
  • 对一名缺乏家族PKD2突变但呈ADPKD样表型的患者,使用65个候选基因的靶向二代测序。

主要发现

  • 在缺乏家族PKD2突变的ADPKD样表型患者中鉴定出COL4A1突变(p.Gln247*),诊断为HANAC综合征。
  • 家系中4名个体携带ADPKD-PKD2,5名患者呈现多种COL4A1相关表型。
  • 3名可能双基因PKD2/COL4A1疾病个体约50岁达到终末期肾病,显著早于任一单基因疾病。

关键数值与推荐

  • ADPKD分子分析在超过90%的病例中可发现PKD1、PKD2或罕见GANAB的致病突变。
  • 靶向二代测序panel包含65个候选基因。

临床怎么用

  • 对ADPKD样表型但缺乏家族PKD2突变的患者,可考虑靶向二代测序以鉴别其他囊性疾病。
  • 精确病因诊断有助于ADPKD患者纳入特异性治疗试验和优化管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The diagnosis of autosomal dominant polycystic kidney disease (ADPKD) relies on imaging criteria in the setting of a positive familial history. Molecular analysis, seldom used in clinical practice, identifies a causative mutation in >90% of cases in the genes PKD1, PKD2, or rarely GANAB. We report the clinical and genetic dissection of a 7-generation pedigree, resulting in the diagnosis of 2 different cystic disorders. Using targeted next-generation sequencing of 65 candidate genes in a patient with an ADPKD-like phenotype who lacked the familial PKD2 mutation, we identified a COL4A1 mutation (p.Gln247*) and made the diagnosis of HANAC (hereditary angiopathy with nephropathy, aneurysms, and muscle cramps) syndrome. While 4 individuals had ADPKD-PKD2, various COL4A1-related phenotypes were identified in 5 patients, and 3 individuals with likely digenic PKD2/COL4A1 disease reached end-stage renal disease at around 50 years of age, significantly earlier than observed for either monogenic disorder. Thus, using targeted next-generation sequencing as part of the diagnostic approach in patients with cystic diseases provides differential diagnoses and identifies factors underlying disease variability. As specific therapies are rapidly developing for ADPKD, a precise etiologic diagnosis should be paramount for inclusion in therapeutic trials and optimal patient management.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Cornec-Le Gall E, Chebib FT, Madsen CD, et al. The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. Am J Kidney Dis. 2018. PMID: 29395486. doi:10.1053/j.ajkd.2017.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。